Pharmacokinetic study in rats after single intravenous and oral administrations of [14C]-ITF-296.
Pharmacokinetics of [14C]-ITF-296 and its metabolites, ITF-1124 and ITF-1577, were studied in rats after a single intravenous (2.5 mg/kg) and oral (10 mg/kg) administration. Radioactivity was measured by LSC while unchanged drug and its metabolites in plasma were assayed by an HPLC-UV method. The absorption of [14C]-ITF-296 after oral administration is practically complete. Elimination of radioactivity occurs mainly in urine (higher than 80%) and the recovery of the dose (higher than 95%) takes place up to 96 h after both treatments. Both by i.v. and p.o. route the results show that the radioactivity is largely excreted in the bile and reabsorbed in the intestine. The tissue distribution study indicates that there is no accumulation or localization of radioactivity in the major organs or blood and no radioactivity levels are found 96 h after either treatment. In addition, whole body autoradiography confirms the tissue distribution pattern, showing no differences between albino and pigmented rats.
Giachetti
C
C
Istituto di Ricerche Biomediche A. Marxer, RBM S.p.A., Colleretto Giacosa (TO), Italy.
Bertolino
M
M
Canali
S
S
Lombardini
E
E
Monzani
M V
MV
Sala
A
A
Zanolo
G
G
D000284:Administration, Oral; D000818:Animals; D001345:Autoradiography; D048588:Benzoxazines; D001646:Bile / Q000378:metabolism; D002250:Carbon Radioisotopes; D007275:Injections, Intravenous; D008297:Male; D009566:Nitrates / Q000097:blood / Q000493:pharmacokinetics*; D009569:Nitric Oxide / Q000378:metabolism; D010078:Oxazines / Q000097:blood / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution
D048588:Benzoxazines; D002250:Carbon Radioisotopes; D009566:Nitrates; D010078:Oxazines; D019275:Radiopharmaceuticals; D009569:Nitric Oxide; C091726:sinitrodil